23:56 , Nov 3, 2017 |  BioCentury  |  Strategy

Broadening Novartis’ NET

Novartis AG’s proposed acquisition of Advanced Accelerator Applications S.A. would broaden the pharma’s neuroendocrine tumor franchise by providing it with a second-line agent -- Lutathera -- that addresses patients with progressive, symptomatic disease. On Oct....
04:51 , Nov 3, 2017 |  BC Week In Review  |  Company News

Novartis offers $3.9B to acquire Advanced Accelerator

Novartis AG (NYSE:NVS; SIX:NOVN) offered to acquire Advanced Accelerator Applications S.A. (NASDAQ:AAAP) for $82 per ADS in a deal the companies say values Advanced Accelerator at $3.9 billion. The price is a 12% premium on...
22:44 , Oct 30, 2017 |  BC Extra  |  Company News

Novartis offers $3.9B to acquire Advanced Accelerator

Novartis AG (NYSE:NVS; SIX:NOVN) offered to acquire Advanced Accelerator Applications S.A. (NASDAQ:AAAP) for $82 per ADS in a deal the companies say values Advanced Accelerator at $3.9 billion. The price is a 12% premium on...